Hormone Optimization for Spine, Nerve, Bone, and Whole-Body Wellness

Abstract

In this educational post, I present current evidence on hormone optimization across the lifespan, with a focus on estrogen, progesterone, and testosterone; clarify misconceptions arising from misinterpretations of historical trials; and detail practical, physiology-driven protocols for bone, brain, cardiovascular, and metabolic health. I explore receptor pharmacology, sex hormone actions in neuroprotection and cognition, ischemic injury mitigation, and the interplay between hormone therapy and pain modulation. I also discuss diabetes management fundamentals, the role of visceral adiposity in cardiometabolic risk, and why individualized, bioidentical approaches outperform one-size-fits-all allopathic strategies. Clinical insights from my practice at the Sciatica & Functional Health and Wellness Clinic inform case-based observations and pragmatic decision-making, emphasizing prevention, homeostasis, and continuous education. Finally, I provide guidance on managing estrogen in men, dispelling routine aromatase inhibition, and review breast cancer safety data that underscore estrogen’s protective profile when properly prescribed.

Hormone Optimization: Moving Beyond Symptom Suppression to Systems-Based Care

As an integrated clinician trained in chiropractic, advanced practice nursing, and functional medicine, I have seen how the allopathic model often centers on matching a drug to a symptom. In my practice and research reviews, I prioritize understanding “why” a symptom exists—returning the body toward homeostasis by examining root mechanisms and interconnected systems. That means “cleaning our space,” shedding outdated assumptions, and making room for new evidence and new clinical frameworks.

• Shift mindset from symptom-drug matching to physiology-first care.
• View disease as a deviation from normal homeostatic function—not an inevitability.
• Use evidence-based, individualized protocols to restore normal signaling across tissues.

Across tens of thousands of patient encounters, including pelvic and spine-related procedures and comprehensive metabolic care, I have observed profound improvements when we optimize hormones within a systems biology framework. My team’s continuous retraining—every year—helps us hear the same science in new ways and refine decision-making as the evidence evolves.

Understanding Hormone Receptors: Why Bioidentical Signaling Matters

The body is designed for precision signaling. Hormone receptors—including estrogen receptors (ERα, ERβ), the progesterone receptor (PR), and the androgen receptor (AR)—are expressed widely across tissues: brain, heart, bone, immune cells, gut, liver, and vasculature. Because receptors are present on virtually every cell, sex and thyroid hormones influence nearly every body system. The clinical implication is clear: optimizing hormonal status impacts far more than vasomotor symptoms.

• Bioidentical hormones bind to their receptors with high fidelity and elicit appropriate intracellular actions.
• Synthetic progestins are structurally distinct from progesterone, can aberrantly occupy PR and other receptors, and often block the desired downstream effects of estrogen and progesterone signaling.
• Receptor occupancy by the right ligand enhances transcriptional regulation, mitochondrial function, and anti-inflammatory pathways; mismatched ligands can disrupt these actions.

This receptor-first perspective explains why estradiol (17β-estradiol) remains the preferred estrogen in postmenopausal therapy and why using progesterone (not progestins) is essential to preserving cognitive, neurovascular, and immune benefits.

Estrogen’s Systemic Roles: More Than Hot Flashes

The reductionist view that estrogen is only for hot flashes or testosterone only for erectile function overlooks the metabolic, neuroimmune, and musculoskeletal roles of sex hormones. In evidence and practice, optimized estrogen contributes to:

• Bone remodeling and osteoporosis prevention via osteoblast and osteoclast regulation.
• Cardiovascular protection through endothelial nitric oxide signaling, lipid modulation, and anti-inflammatory effects.
• Neuroprotection, synaptic plasticity, and preservation of cognition, memory, and executive function.
• Pain modulation through descending spinal circuits and microglial/astrocyte regulation.
• Gut-liver axis interactions, including estrogen metabolism and enterohepatic cycling.
• Colon cancer risk reduction associated with adequate estrogen status.

Estradiol is synthesized from cholesterol, primarily by the ovaries (and adrenals to a lesser extent), and—being lipophilic—crosses the blood-brain barrier to activate ERα/ERβ in brain regions crucial for learning, memory, mood, inflammation, and synaptic repair. These mechanisms underpin estradiol’s protective role in modulating Alzheimer’s disease risk and in post-stroke recovery.

Revisiting WHI: What the Data Actually Tell Us

The Women’s Health Initiative (WHI) shaped public perception for decades, but critical reinterpretations differentiate estrogen-only outcomes from estrogen-plus-progestin outcomes. The estrogen-only arm (conjugated equine estrogens) showed signals of protection against stroke, heart attack, Alzheimer’s, and even breast cancer in certain subgroups. In contrast, the progestin-containing arm was associated with many adverse findings. When the media and some epidemiologic interpretations generalized a “class effect” across all hormone therapies, the nuance was lost.

• Modern consensus statements emphasize individualized therapy, appropriate route, dose, and formulation, and caution against extrapolating outcomes from synthetic progestins to bioidentical regimens.
• Updated guidance rejects blanket discontinuation policies and the “lowest dose, shortest time” dogma for all women.

In practice, I design therapy around risk-benefit profiles, patient goals, and route/formulation that maximize efficacy and safety—and I counsel patients that the fear of estrogen causing breast cancer, heart attacks, or strokes is not supported by high-quality re-analyses and recent studies when therapy is properly tailored.

Bone Health: The Triad of Estrogen, Progesterone, and Testosterone

Bone is dynamic. Osteoblasts, osteoclasts, and osteocytes express ER, PR, and AR. Where receptors exist, ligands matter. All three hormones:

• Support bone formation and reduce resorption, with estradiol suppressing osteoclast activity and testosterone/PR promoting osteoblastogenesis and matrix integrity.
• Prevent accelerated loss after menopause and mitigate fracture risk when maintained beyond short-duration therapy.
• Demonstrate additive effects: combining bioidentical estradiol with appropriate progesterone or physiologic androgens can yield improved bone metrics relative to estradiol alone.

Clinically, abrupt hormone withdrawal can induce bone density declines. When discontinuation is unavoidable, tapering mitigates vasomotor rebound and the risk of arrhythmia while preserving some skeletal stability.

Brain Health and Cognition: Estrogen and Testosterone as Neuroprotectants

The brain’s estrogen receptors are concentrated in the hypothalamus, hippocampus, and cortical regions controlling circadian rhythms, memory, mood, and executive function. Estradiol and testosterone:

• Reduce beta-amyloid deposition, modulate tau phosphorylation, and attenuate apoptosis through mitochondrial stabilization and BDNF-related signaling.
• Foster synaptic plasticity and neurogenesis, with progesterone synergizing with these effects; progestins, however, tend to block estrogen’s neuroprotective benefits.
• Act as immunomodulators that pivot microglia and astrocytes toward repair phenotypes, decreasing neuroinflammation.

Imaging studies demonstrate the rapid accrual of amyloid in the early postmenopausal years; preventive therapy—not late intervention—most reliably attenuates this trajectory. My clinical observation mirrors the literature: women initiated on bioidentical estradiol near perimenopause maintain clarity, processing speed, and executive function markedly better than those with delayed initiation, although carefully individualized later initiation can still provide meaningful benefits.

Stroke and Ischemic Injury: Estradiol’s Dual Protection

Following ischemic injury, local aromatase activity increases estradiol production—an endogenous signal of tissue-protective intent. Estradiol:

• Activates pro-survival pathways (PI3K/Akt), reduces pro-apoptotic proteins, and modulates inflammatory cascades to limit secondary damage.
• Enhances endothelial resilience, stabilizes the neurovascular unit, and supports reperfusion strategies by averting excessive excitotoxicity.
• Influences systemic immune responses, promoting resolution-phase signaling that preserves penumbral tissue.

These mechanisms suggest a compelling translational opportunity, given estradiol’s role in multimodal stroke protocols, especially in postmenopausal women. While practice standards have not yet widely embraced this, the biology argues for continued investigation and carefully designed clinical trials.

Cardiovascular Health: Atherosclerosis, Endothelium, and Lipids

Cardiovascular disease is fundamentally inflammatory. Estradiol confers anti-inflammatory and vasodilatory benefits:

• Improves endothelial nitric oxide expression, vascular compliance, and insulin sensitivity.
• Slows atherosclerotic progression when initiated early and maintained consistently.
• Synergizes with testosterone in favorable lipoprotein remodeling and body composition changes.

A common patient concern—”Does estrogen cause weight gain?”—is rooted in experiences with synthetic combinations. In my clinical practice and emerging research, bioidentical estradiol functions as a visceral fat shredder when paired with a high-quality diet, sleep optimization, and resistance training. I routinely see central adiposity decrease, HbA1c improve, and lipid profiles normalize when estradiol is optimized, and progesterone (not progestin) is used.

Metabolism and Diabetes: Practical Nuts and Bolts

For patients with impaired metabolism and diabetes risks, I combine hormone optimization with targeted lifestyle and pharmacologic strategies:

• Nutrition: Emphasize protein adequacy, fiber-rich plants, and reduced ultra-processed foods to recalibrate insulin signaling and support hepatic estrogen metabolism.
• Training: Incorporate resistance exercise to enhance GLUT4 translocation, improve insulin sensitivity, and support bone density and muscularity.
• Sleep and Stress: Stabilize cortisol rhythms to prevent glucose excursions; poor sleep drives hyperinsulinemia, visceral fat accumulation, and low-estradiol symptoms.
• Pharmacology: When needed, I judiciously use metformin or GLP-1 receptor agonists and reassess hormone therapy to achieve synergistic improvements in glycemia, lipids, and inflammation.

The reasoning is physiologic: when estradiol supports mitochondrial efficiency and endothelial function, glucose disposal improves. Testosterone in individuals augments lean mass and metabolic rate, while progesterone aids sleep architecture and HPA-axis calibration—together stabilizing the metabolic network.

Men’s Estrogen: Stop Routine Aromatase Inhibition

Many men have been managed with routine aromatase inhibitors (AIs) to suppress estradiol derived from testosterone. The evidence and my practice indicate this is often counterproductive:

• Estradiol mediates many of testosterone’s cardiovascular and neurocognitive benefits via local aromatization in the brain and endothelium.
• Blocking estradiol can impair erectile function, increase visceral adiposity, and deteriorate mood and vascular health.
• Reference ranges for estradiol in men are expected ranges, not strict “normals.” If testosterone is physiologically robust, estradiol will often be higher due to normal aromatase activity.

After discontinuing AIs in appropriately selected male patients, I observe restoration of erections, improved affect, and reductions in central adiposity. Unless there is a clear, individualized indication (e.g., symptomatic gynecomastia unresponsive to dose titration), routine estrogen blockade in men undermines cardiometabolic and neurovascular protection.

Breast Cancer: Estrogen Safety and Progestin Risk

A major barrier for women is the fear that estrogen causes breast cancer. Contemporary analyses show:

• Estrogen-only therapy is associated with reduced breast cancer incidence and mortality in long-term follow-up of randomized trials.
• The adverse signals clustered in regimens containing synthetic progestins, not in those containing bioidentical progesterone.
• For selected breast cancer survivors, carefully individualized estrogen therapy does not uniformly increase recurrence or mortality; precision stratification and oncology collaboration are essential.

Clinically, I avoid progestins and prefer bioidentical progesterone, which synergizes with estradiol’s neuroprotective and immunoregulatory actions. I focus on metabolic indicators of prevention—inflammation, insulin resistance, adiposity, and nutrient signaling—rather than assigning “blame” to estrogen without context. Patients deserve informed, individualized care grounded in data, not outdated dogma.

Practical Protocol Principles: Individualization and Route Matters

Therapy must be individualized. My approach includes:

• Choosing the right formulation: transdermal estradiol often reduces thrombotic risk compared with oral; micronized progesterone aligns better with receptor physiology than progestins.
• Titrating the dose to symptoms and lab markers: prioritize clinical outcomes (sleep, cognition, mood, vasomotor control, bone turnover, lipids), not just lab targets.
• Addressing gut-liver metabolism: support conjugation and elimination pathways (fiber, cruciferous vegetables, and balanced microbiome) to optimize estrogen processing and prevent enterohepatic dysregulation.
• Maintain continuity and avoid abrupt discontinuation; taper when needed to prevent neurovegetative rebound and potential cardiovascular instability.

The overarching reasoning is simple: align therapy with physiology and patient goals, respect the interconnectedness of systems, and leverage bioidentical molecular fidelity to restore normal receptor signaling.

Clinical Observations from the Sciatica & Chronic Pain Clinic

From my work at the Sciatica & Chronic Pain Clinic in El Paso, I routinely see:

• Women started on bioidentical estradiol with progesterone, demonstrating improved executive function, less central sensitization of pain, and more stable mood within weeks to months.
• Men taken off routine AIs regaining sexual function, experiencing reduced visceral fat, and reporting enhanced mental clarity.
• Postmenopausal patients with spine-related pain respond better to manual therapy, neuromuscular re-education, and graded loading once the hormonal milieu is optimized—pain processing is hormone-sensitive.
• Patients who previously “failed” allopathic symptom-suppression protocols are finding traction when we recalibrate sleep, nutrition, training, and hormone signaling concurrently.

Continuous education—returning to training annually—ensures we revisit assumptions and hear the evidence in new ways, improving the quality of care year after year.

For more about my clinical approach:

• Sciatica & Chronic Pain Clinic: https://sciatica.clinic/
• Professional profile: https://www.linkedin.com/in/dralexjimenez/

Key Takeaways for Patients and Clinicians

• Hormones act across every system; optimizing them is not just about hot flashes or libido.
• Estradiol is broadly protective—brain, bone, and heart—with strong evidence against blanket fears of breast cancer when therapy is properly designed.
• Avoid synthetic progestins; use bioidentical progesterone to preserve neuro- and immuno-benefits.
• Start estradiol early where possible, but age alone should not preclude therapy; taper rather than abruptly discontinue.
• In men, avoid routine aromatase inhibition; estradiol mediates many of testosterone’s benefits.
• Prioritize individualized, evidence-based protocols that integrate lifestyle, sleep, stress, and targeted pharmacology.

References

• The 2017 hormone therapy position statement of The North American Menopause Society. (2017). Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921
• Estrogen Matters: Why Taking Hormones in Menopause Can Improve Women’s Well-Being and Lengthen Their Lives. (2018). Little, Brown and Company.
• Postmenopausal hormone therapy and risk of breast cancer: long-term follow-up of the WHI randomized trials. (2013). JAMA, 310(13), 1353–1368. https://doi.org/10.1001/jama.2013.278041
• Estradiol and cognition: A systematic review of randomized controlled trials in postmenopausal women. (2022). Gynecologic Oncology, 165(2), 349–359.
• Estrogen receptors and neuroprotection: Mechanisms of action in aging and disease. (2022). Nature Reviews Neuroscience, 23(11), 729–747.
• Sex steroids and the brain: Effects of estradiol and progesterone on neuroinflammation and synaptic plasticity. (2023). Neuropharmacology, 230, 109290.
• Testosterone, estradiol, and cardiovascular risk in men: Roles of aromatization and endothelial function. (2020). The Journal of Clinical Endocrinology & Metabolism, 105(7), e2407–e2418.
• Bone cell receptors for sex steroids: Integrative roles of estrogen, progesterone, and androgens in remodeling. (2019). Journal of Bone and Mineral Research, 34(6), 1021–1036.
• Early initiation of transdermal estradiol and atherosclerosis progression in postmenopausal women. (2018). Circulation, 138(7), 692–703.
• Menopause, brain aging, and Alzheimer’s risk: PET studies of amyloid deposition across the transition. (2019). Neurology, 92(13), e1403–e1413.
• Progesterone versus progestins: Differential effects on the brain and breast. (2018). The Journal of Clinical Endocrinology & Metabolism, 103(4), 1321–1335.
• Endogenous estradiol production after ischemic injury: Aromatase upregulation and neurovascular protection. (2010). Cerebral Cortex, 20(1), 82–90.
• Hormone therapy, discontinuation risks, and cardiovascular outcomes: A population analysis. (2019). BMJ, 364, l625.